Novartis AG (NVS)
| Market Cap | 291.47B +27.8% |
| Revenue (ttm) | 56.58B +6.3% |
| Net Income | 13.53B +5.2% |
| EPS | 6.98 +9.5% |
| Shares Out | 1.91B |
| PE Ratio | 21.54 |
| Forward PE | 17.25 |
| Dividend | $3.08 (1.93%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 1,588,015 |
| Open | 157.50 |
| Previous Close | 154.14 |
| Day's Range | 157.00 - 160.57 |
| 52-Week Range | 112.34 - 170.46 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 154.57 (-3.33%) |
| Earnings Date | Jul 21, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $154.57, which is a decrease of -3.33% from the latest price.
News
Novartis AG (NVS) Stock Up 3.7% but GF Value Says Overvalued -- GF Score: 82/100
Novartis AG (NVS) Stock Up 3.7% but GF Value Says Overvalued -- GF Score: 82/100
Novartis (NVS) Gains EU Approval for Itvisma Gene Therapy for SMA
Novartis (NVS) Gains EU Approval for Itvisma Gene Therapy for SMA
Novartis (NVS) Secures Approval for Itvisma in SMA Treatment
Novartis (NVS) Secures Approval for Itvisma in SMA Treatment
Novartis receives EC approval for Itvisma for spinal muscular atrophy
Novartis (NVS) announced that the European Commission, EC, has approved Itvisma for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy, SMA,…
Novartis Granted EC Approval For Itvisma In Treating Spinal Muscular Atrophy
(RTTNews) - Novartis AG (NVS), a pharmaceutical company, on Thursday reported receiving approval from the European Commission (EC) for Itvisma, a gene therapy developed for the treatment of children, ...
Novartis Announces Approval Of Itvisma In Europe For Spinal Muscular Atrophy
(RTTNews) - Novartis (NVS, NOVN.SW) announced that the European Commission has approved Itvisma or onasemnogene abeparvovec for the treatment of children two years and older, teens and adults living w...
3 European Stocks to Carry Investors Through the Back Half of 2026
The first half of the year is over, and it may surprise some investors that European stocks are nearly at parity with U.S. stocks. The tale of the tape as of June 30 tells the story:
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell
Micron surged after strong Q3 results, robust AI-driven memory demand and a bullish Q4 outlook. See which ETFs have notable exposure.
Top Stock Reports for JPMorgan, Novartis & Qualcomm
JPMorgan, Novartis and Qualcomm headline today's top stock reports, highlighting growth drivers, competitive pressures and key catalysts ahead.
Novartis Eyes $5 Billion Pluvicto Opportunity
Novartis Eyes $5 Billion Pluvicto Opportunity
Novartis Targets Hard-to-Treat Cancers
Novartis Targets Hard-to-Treat Cancers
Pre-Market Most Active for Jun 24, 2026 : WEN, NOK, ABSI, RUN, SQQQ, SPCX, CCXI, NVS, NIO, INFQ, AMC, SMR
The NASDAQ 100 Pre-Market Indicator is up 160.39 to 29,507.66. The total Pre-Market volume is currently 102,362,656 shares traded.The following are the most active stocks for the pre-market session: W...
Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Antares Therapeutics said on Wednesday it entered a collaboration with Novartis that could be worth up to about $1.9 billion, aiming to develop therapies for historically hard-to-drug cancer targets...
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies
BOSTON--(BUSINESS WIRE)--Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a strategi...
Zacks Investment Ideas feature highlights: IBB, Novartis, Pfizer and Eli Lilly's
IBB, Novartis, Pfizer and Eli Lilly's have been highlighted in this Investment Ideas article.
The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs
The investigation comes after Berlin said it would require drugmakers to offer bigger discounts on medicines.
U.S. opens tariff probe targeting Germany's drug pricing policies
The U.S. said the probe will examine whether "persistent underpayment" for medicines by Germany is discriminatory. "President Trump has made clear that American patients should not be shouldering a di...
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track...
Novartis (NVS) Advances RNA Therapy Del-Brax in FSHD Trials
Novartis (NVS) Advances RNA Therapy Del-Brax in FSHD Trials
Novartis (NVS) Achieves Key Milestone with Rhapsido in CIndU Trial
Novartis (NVS) Achieves Key Milestone with Rhapsido in CIndU Trial
Novartis' Rhapsido Shows Promise In Chronic Inducible Urticaria
(RTTNews) - Novartis (NVS) unveiled late-breaking Phase 3 RemIND trial data at the EAACI Congress, highlighting the potential of Rhapsido (remibrutinib) as the first targeted therapy for chronic induc...
Novartis announces Rhapsido met primary endpoints in RemIND trial
Novartis (NVS) presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology, EAACI, Congress showing that Rhapsido met its primary endpoints across the three most…
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido® (remibrutinib) met its pr...
Is Novartis AG (NVS) Overvalued After 3.9% Rally? GF Value Says Overvalued
Is Novartis AG (NVS) Overvalued After 3.9% Rally? GF Value Says Overvalued
Novartis says rare muscle disease drug shows promise in early trial
Novartis said on Thursday an experimental drug, which it acquired as part of its $12 billion takeover of Avidity, showed promise in an early-to-mid-stage study in patients with a type of genetic mu...